Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme.
Recurrent diffuse intrinsic brain stem glioblastoma multiforme carries an extremely poor prognosis and a median survival of less than 7 months. In this article, the authors report good results in a 40-year-old man diagnosed with glioblastoma multiforme who received antineoplastons. The patient's brain tumor was diagnosed in May 1999, and he subsequently underwent subtotal tumor resection and standard radiation therapy. Magnetic resonance imaging and positron emission tomography scans documented his tumor recurrence. Approximately 2 months after completion of radiation therapy, he was admitted for administration of intravenous antineoplastons A10 and AS2-1 through a subclavian venous catheter by intermittent bolus injections 6 times per day using a portable pump. Administration of antineoplastons A10 and AS2-1 was over 655 consecutive days with the exception of a few short interruptions. The maximum dosage of A10 was 8.15 g/kg/d and AS2-1 0.35 g/kg/d. Antineoplastons A10 and AS2-1 administration was very well tolerated with only mild reversible side effects. Follow-up magnetic resonance imaging and positron emission tomography scans revealed decrease and eventually disappearance of the tumor. A complete response was documented after approximately 1 year of antineoplastons A10 and AS2-1 administration. More than 4 years later, off antineoplastons A10 and AS2-1, the patient is tumor free, able to carry on normal activities, and works full-time, and his Karnofsky Performance Status increased from 50 to 100. Extensive phase II trials with antineoplastons A10 and AS2-1 in patients with glioblastoma multiforme are nearing completion. These trials may provide more data regarding the efficacy of antineoplastons A10 and AS2-1 in the treatment of glioblastoma multiforme in untreated patients compared to the results in those patients with tumor recurrence after radiation therapy.
Department of Internal Medicine, Burzynski Clinic, Houston, Texas 77082, USA. info@burzynskiclinic.com
Stanislaw R
SR
Burzynski
Robert I
RI
Lewy
Robert
R
Weaver
Tomasz
T
Janicki
Gabor
G
Jurida
Mohammad
M
Khan
Chymbeelyn B
CB
Larisma
Jaroslaw
J
Paszkowiak
Barbara
B
Szymkowski
D000328:Adult; D044482:Benzeneacetamides / Q000627:therapeutic use*; D020295:Brain Stem Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D018572:Disease-Free Survival; D004338:Drug Combinations; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005973:Glutamine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006304:Health Status; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D010648:Phenylacetates / Q000627:therapeutic use*; D010881:Piperidones / Q000627:therapeutic use*; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D044482:Benzeneacetamides; D004338:Drug Combinations; D010648:Phenylacetates; D010881:Piperidones; D005973:Glutamine; C092038:antineoplaston AS 2-1; C052091:antineoplaston A10